Biodexa Pharmaceuticals (BDRX) Competitors $5.54 +0.07 (+1.28%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.50 -0.04 (-0.81%) As of 08/29/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. CLRB, IMNN, MRKR, LIXT, SNGX, NEUP, PRPH, NXTC, APM, and EPIXShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Cellectar Biosciences (CLRB), Imunon (IMNN), Marker Therapeutics (MRKR), Lixte Biotechnology (LIXT), Soligenix (SNGX), Neuphoria Therapeutics (NEUP), ProPhase Labs (PRPH), NextCure (NXTC), Aptorum Group (APM), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Cellectar Biosciences Imunon Marker Therapeutics Lixte Biotechnology Soligenix Neuphoria Therapeutics ProPhase Labs NextCure Aptorum Group ESSA Pharma Cellectar Biosciences (NASDAQ:CLRB) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Do analysts prefer CLRB or BDRX? Cellectar Biosciences currently has a consensus target price of $375.00, indicating a potential upside of 7,600.21%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cellectar Biosciences is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, CLRB or BDRX? Cellectar Biosciences has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Which has better valuation and earnings, CLRB or BDRX? Biodexa Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$19.91-0.24Biodexa Pharmaceuticals$470K7.31-$7.32MN/AN/A Is CLRB or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -486.67% -150.57% Biodexa Pharmaceuticals N/A N/A N/A Does the media prefer CLRB or BDRX? In the previous week, Cellectar Biosciences had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.87 beat Cellectar Biosciences' score of 0.61 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cellectar Biosciences Positive Biodexa Pharmaceuticals Very Positive Do insiders and institutionals believe in CLRB or BDRX? 16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryBiodexa Pharmaceuticals beats Cellectar Biosciences on 7 of the 12 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.39M$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E RatioN/A20.9283.2726.61Price / Sales7.31200.54451.26176.46Price / CashN/A44.0537.7059.65Price / Book1.908.0710.556.59Net Income-$7.32M-$53.98M$3.27B$266.12M7 Day Performance-15.93%-0.88%0.47%0.17%1 Month Performance-35.86%6.20%5.93%3.03%1 Year PerformanceN/A7.13%48.79%19.98% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.6813 of 5 stars$5.54+1.3%N/AN/A$3.39M$470K0.0020Positive NewsCLRBCellectar Biosciences2.0217 of 5 stars$4.77+1.6%$375.00+7,755.0%-92.6%$15.31MN/A-0.2410Gap UpIMNNImunon1.6838 of 5 stars$6.23-1.9%$232.50+3,631.9%-63.7%$15.24M$500K-0.4830MRKRMarker Therapeutics3.4068 of 5 stars$1.16-8.3%$13.17+1,040.0%-73.6%$15.20M$6.59M-0.8660Gap UpHigh Trading VolumeLIXTLixte Biotechnology0.1561 of 5 stars$3.27-0.5%N/A+147.2%$14.93MN/A-2.544SNGXSoligenix1.9735 of 5 stars$3.32+6.2%$6.00+80.6%-5.2%$14.26M$120K-0.8820Gap UpNEUPNeuphoria Therapeutics1.9756 of 5 stars$7.55+2.9%$21.00+178.1%N/A$14.19M$10K0.00N/ANews CoverageAnalyst ForecastAnalyst RevisionGap UpPRPHProPhase Labs1.374 of 5 stars$0.34+0.4%N/A-85.9%$14.00M$6.77M-0.27130Positive NewsGap DownNXTCNextCure4.3777 of 5 stars$5.23+0.1%$25.50+388.0%-73.3%$13.98MN/A-0.2090Positive NewsAPMAptorum Group1.0743 of 5 stars$2.47+5.8%N/A-31.6%$13.72MN/A0.0030Positive NewsEPIXESSA Pharma3.069 of 5 stars$0.28-64.9%$2.00+627.3%-95.6%$13.15MN/A-0.5050Dividend AnnouncementOptions VolumeGap DownHigh Trading Volume Related Companies and Tools Related Companies Cellectar Biosciences Competitors Imunon Competitors Marker Therapeutics Competitors Lixte Biotechnology Competitors Soligenix Competitors Neuphoria Therapeutics Competitors ProPhase Labs Competitors NextCure Competitors Aptorum Group Competitors ESSA Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
